Validating AI in GxP Environments: The Flex Databases Approach to eTMF Compliance
June 30, 2026
The pharmaceutical industry faces a familiar paradox: the tools that promise to make regulatory compliance faster and smarter also introduce the most complex new compliance questions. Nowhere is this more visible than in AI-powered Trial Master File (TMF) management. At Flex Databases, we have developed a validation framework rooted in GxP principles, risk-based thinking, and one core conviction – AI is not a shortcut around accountability, but another step in a long history of process automation.
Why AI in eTMF?
TMF activities – document classification, metadata assignment, completeness checks – are high-volume, repetitive, and detail-intensive. AI addresses these pain points directly:
- Efficiency – real-time document processing at a scale no manual team can match
- Cost Reduction – less manual classification overhead across large multi-site trials
- Accuracy – consistent classification logic applied uniformly across thousands of documents
- Scalability – handles growing TMF volumes without proportional headcount increase
- Compliance – automated quality checks reduce gaps that accumulate silently in manual workflows
- Focus on Core Activities – frees clinical staff for higher-order judgment tasks
Key principle: Efficiency gains only matter if the underlying AI behavior is trustworthy. A misclassified document in a TMF is not merely an inconvenience – it can mean a missing record at inspection, a data integrity finding, or a delayed submission.
A Regulatory Landscape Still Taking Shape
AI systems used in regulated environments must be subject to the same risk-based validation logic applied to any GxP-relevant computerized system. The current regulatory guidance draws from:
- FDA: AI/ML for Drug Development Discussion Paper
- FDA: CDER Framework for Regulatory Advanced Manufacturing Evaluation (FRAME)
- MHRA: Software and Artificial Intelligence (AI) as a Medical Device
- EU: Artificial Intelligence Act
- ISPE GAMP® 5: A Risk-Based Approach to Compliant GxP Computerized Systems (Second Edition)
None of these offers a complete prescriptive blueprint for eTMF AI validation specifically. What they share, however, is a common foundation: the probabilistic and adaptive nature of AI makes demonstrating fitness for intended use more important – not less – than for conventional software.
Traditional vs. AI Validation: A Fundamental Shift
Understanding why AI validation is harder starts with understanding how AI systems differ from traditional software. The table below captures the core differences that drive the need for a distinct validation approach:
| Traditional Applications | AI Applications | |
|---|---|---|
| Nature | Deterministic software producing the same output for the same input. Validation focuses on verifying specified functionality. | AI/ML systems are typically probabilistic, producing outputs based on learned patterns rather than explicit programming. Validation focuses on demonstrating fitness for intended use and acceptable performance. |
| Role of Data | Data are processed to produce defined business outcomes. | Data are used both to operate the system and, for machine learning models, to train, validate, and test model performance. Training, validation, and test datasets should be appropriately separated. |
| Expected Behaviour | Behaviour is predictable and reproducible under the same conditions. | Outputs may vary within defined performance limits. Performance depends on model design, training data, configuration, and intended use. |
| Failure Modes | Primarily deterministic software defects or configuration errors. | May include software defects as well as model limitations, data quality issues, statistical errors, bias, hallucinations, concept drift, or prompt sensitivity. |
| Validation Focus | Verification that requirements are correctly implemented. | Verification of intended functionality plus validation of model performance, risk controls, human oversight, explainability (where appropriate), and ongoing performance monitoring. |
AI-enabled systems remain subject to the same risk-based validation principles applied to other GxP computerized systems. In accordance with GAMP® 5 Second Edition and FDA Computer Software Assurance (CSA), the validation effort should be commensurate with risk. AI functionality requires additional consideration of training data, model performance, human oversight, explainability where appropriate, and lifecycle monitoring.
Reframing the Question: Process, Not Model
The most important conceptual shift in our approach: we validate the complete business process supported by AI, not the AI model in isolation.
Our validation objective is to demonstrate that AI-supported functions – document classification, metadata assignment, and quality checks – consistently perform as intended and support the maintenance of a complete, accurate, and inspection-ready TMF. This shifts focus from model metrics to operational outcomes, which is the right frame for any GxP system.
Risk Factors and Data Quality
Before functional validation begins, we address the risk factors that can undermine AI reliability in GxP environments:
| Risk Factor | What It Means in Practice |
|---|---|
| Training data quality and representativeness | Incomplete, biased, inconsistent, or unrepresentative training data may lead to systematic errors or reduced model performance. |
| Independent training, validation and test datasets | Model performance cannot be reliably demonstrated if datasets are not appropriately separated or representative of the intended use. |
| Out-of-distribution inputs (edge cases) | Documents or scenarios not represented during training may produce unexpected or unreliable outputs. |
| Human oversight | AI-generated outputs should be reviewed by qualified personnel before being used for GxP decisions, where appropriate. |
| Domain or regulatory change | New document types, templates, or regulatory expectations introduced after model training may require model review, retraining, or revalidation. |
| Performance monitoring | Ongoing monitoring is necessary to detect degradation in model performance over time and ensure continued fitness for intended use. |
These risks should be considered during AI risk assessment and validation planning to determine the appropriate level of verification, human oversight, and ongoing performance monitoring in accordance with GAMP® 5 Second Edition and FDA Computer Software Assurance (CSA) principles.
The Validation Lifecycle: GAMP® 5 and CSA-Aligned
Validation activities are structured using a risk-based lifecycle approach aligned with GAMP® 5 Second Edition and Computer Software Assurance principles. The level of verification, documentation, and ongoing monitoring is determined by intended use, GxP impact, data integrity risk, model behavior, and the extent of human oversight.
| GAMP® 5 Lifecycle Phase | Validation / Verification Activities | AI / Data Lifecycle Considerations | Documentation / Evidence |
|---|---|---|---|
| Concept | Define intended use and AI functionalityDefine expected business outcomeIdentify GxP impact and level of human oversight | Identify data sources and intended inputsAssess data suitability and quality | Intended UseAI Functional DescriptionInitial Risk Assessment |
| Specification | Define functional and performance requirementsDefine acceptance criteria and success metricsDefine human review and decision points | Define training, validation and test datasetsEnsure dataset independence and representativeness | Functional SpecificationData SpecificationValidation Plan |
| Risk Assessment | Assess impact on patient safety, product quality and data integrityIdentify AI-specific risks (bias, hallucinations, false positives/negatives, explainability)Define mitigation measures and residual risk | Assess data quality risksAssess model limitations and intended operating conditions | Functional Risk AssessmentRisk Control Measures |
| Testing / Verification | Verify functional requirementsChallenge representative and edge-case scenariosCompare AI output with predefined acceptance criteria and, where applicable, human reviewVerify audit trail, security and data integrity controls | Execute testing using independent validation/test datasetsEvaluate model performance against predefined criteria | Test ScriptsTest EvidenceTraceability MatrixSummary Report |
| Release / Operation | Deploy through controlled change managementTrain usersDefine operational procedures and human oversight responsibilities | Control model versions and configurationMaintain data integrity during operation | Release DocumentationTraining RecordsChange Records |
| Performance Monitoring | Periodically review model performanceMonitor incidents, deviations and user feedbackDefine triggers for retraining, re-verification or revalidation | Monitor for data drift, concept drift and changes in intended useEvaluate continued fitness for intended use | Performance Review RecordsPeriodic ReviewChange ControlRevalidation Documentation (where applicable) |
Supporting Customers Through Validation
End-user organizations must be able to demonstrate, on their own terms, that the system is fit for its intended use. To support this, Flex Databases provides a comprehensive validation package:
- Validation certification (pre-validated status)
- User Requirements Specification
- IQ documentation
- Traceability Matrix
- OQ Testing Summary
- User Acceptance Testing scenarios
- Maintenance documentation (support, backup)
- Training Certificates
- Vendor Qualification supportive documents
Beyond documentation, customer-side validation responsibilities include:
- Assign responsibilities
- Manage risks
- Document testing
- Control process
- Keep training
- Review changes
- Ensure security
Validation Does Not End at Go-Live
This is where AI validation fundamentally differs from traditional software validation. A conventional system, once validated, behaves deterministically. AI systems are different: their behavior is a function of the data they were trained on, and that data’s relationship to the world can change.
Our ongoing monitoring framework addresses:
- Performance tracking – continuous monitoring of AI outputs against acceptance criteria established during validation
- Data and concept drift detection – identifying when real-world TMF content diverges from the training distribution, or when the meaning of that content changes
- Anomaly investigation – systematic root cause analysis of identified misclassifications, not treatment as isolated incidents
- Change control – any change to the AI model (retraining, architectural updates, data pipeline changes) triggers formal impact assessment and, where necessary, revalidation
- Periodic re-verification – scheduled review of performance metrics with defined remediation measures
AI as a Tool, Not a Replacement for Accountability
Running through all of this is a principle we hold consistently: AI is an automation and decision-support tool. It does not and cannot replace human accountability for TMF quality.
Data integrity obligations, inspection readiness requirements, and the professional accountability of clinical operations staff are not transferred to an algorithm when AI is introduced into a TMF workflow. They remain with the users and process owners. By combining AI-driven efficiency with robust validation practices, documented human oversight, and transparent evidence generation, we help our customers adopt AI with confidence – while maintaining inspection readiness and regulatory compliance.
